WE ARE TARGETING PAIN AT ITS SOURCE
Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance
and optimize the ability of each non-addictive product in our pipeline.
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain.
Virpax has global rights to a patented metered-dose topical spray film delivery technology for musculoskeletal pain.
Virpax has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.
Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.